MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New stem cell transplant aims to cut dangerous side effects in blood cancer patients
Disease control Recruiting nowThis study tests a special stem cell transplant for children and adults with blood cancers like leukemia. The transplant uses stem cells that have had certain immune cells removed to lower the risk of graft-versus-host disease, a serious complication. About 70 participants will r…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Engineered immune cells take aim at returning leukemia
Disease control Recruiting nowThis early-phase trial tests a new type of immunotherapy for children and adults whose acute leukemia has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered donor immune cells (T cells) that are designed to recognize and attack …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:57 UTC
-
New combo aims to wipe out hidden cancer cells after chemo
Disease control Recruiting nowThis study tests whether two drugs, fruquintinib and tislelizumab, can control leftover cancer cells in people with colorectal cancer who have completed chemotherapy but still show signs of minimal residual disease (MRD) on a blood test. About 20 adults with stable disease will r…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
Engineered immune cells take aim at lingering colorectal cancer
Disease control Recruiting nowThis early-phase trial tests a new combination treatment for people with colorectal cancer who have minimal residual disease (MRD) — tiny amounts of cancer left after standard therapy. The treatment uses specially engineered natural killer (NK) cells from donated cord blood, desi…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Massive cancer biobank aims to fuel precision medicine breakthroughs
Knowledge-focused Recruiting nowThis study is creating a large collection of blood and tissue samples from 100,000 adults with cancer. The samples and medical information will be stored and shared with researchers to develop better tests and treatments. The goal is to advance precision medicine and improve earl…
Matched conditions: MINIMAL RESIDUAL DISEASE
Sponsor: Caris Science, Inc. • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:51 UTC
-
AI blood test could spot lung cancer return earlier
Knowledge-focused Recruiting nowThis study looks at whether advanced blood tests and artificial intelligence can help detect lung cancer recurrence earlier and without invasive procedures. About 100 adults who had surgery for stage IB-IIIA lung cancer and received standard chemo-immunotherapy before surgery wil…
Matched conditions: MINIMAL RESIDUAL DISEASE
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:06 UTC